Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

APRV for ARDS: the complexities of a mode and how it affects even the best trials.

Mireles-Cabodevila E, Dugar S, Chatburn RL.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1058-S1063. doi: 10.21037/jtd.2018.03.156. No abstract available.

2.

A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.

Moreno-Ulloa A, Nájera-García N, Hernández M, Ramírez-Sánchez I, Taub PR, Su Y, Beltrán-Partida E, Ceballos G, Dugar S, Schreiner G, Best BM, Ciaraldi TP, Henry RR, Villarreal F.

Food Funct. 2018 Jan 24;9(1):307-319. doi: 10.1039/c7fo01028a.

PMID:
29171848
3.

Acute Orthodeoxia: Evaluation Using Point-of-Care Ultrasound Imaging.

Vashisht R, Dugar S, Alappan N, Moghekar A.

Ann Am Thorac Soc. 2017 Apr;14(4):594-596. doi: 10.1513/AnnalsATS.201612-972CC. No abstract available.

PMID:
28362532
4.

On the Need for Standard Definitions and Education to Optimize Patient-Ventilator Interactions.

Mireles-Cabodevila E, Dugar S.

Respir Care. 2017 Feb;62(2):248-249. doi: 10.4187/respcare.05452. No abstract available.

5.

All Shock States Are Not the Same. Systolic Anterior Motion of Mitral Valve Causing Left Ventricular Outflow Tract Obstruction in Septic Shock.

Dugar S, Latifi M, Moghekar A, Duggal A.

Ann Am Thorac Soc. 2016 Oct;13(10):1851-1855. No abstract available.

PMID:
27726435
6.

A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects.

Gutiérrez-Salmeán G, Meaney E, Lanaspa MA, Cicerchi C, Johnson RJ, Dugar S, Taub P, Ramírez-Sánchez I, Villarreal F, Schreiner G, Ceballos G.

Int J Cardiol. 2016 Nov 15;223:500-506. doi: 10.1016/j.ijcard.2016.08.158. Epub 2016 Aug 8.

PMID:
27552564
7.

Killing Glioma 'Stem-like' Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins.

Gorin FA, Pasupuleti N, Mahajan D, Dugar S.

Anticancer Agents Med Chem. 2017;17(1):40-47. Review.

PMID:
27357540
8.

Middle-Aged Woman With Shock.

Dugar S, Kantamneni P, Lane CR, Moghekar A.

Chest. 2016 Feb;149(2):e45-e47. doi: 10.1016/j.chest.2015.08.025. No abstract available.

PMID:
26867854
9.

Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.

Dugar S, Hollinger FP, Mahajan D, Sen S, Kuila B, Arora R, Pawar Y, Shinde V, Rahinj M, Kapoor KK, Bhumkar R, Rai S, Kulkarni R.

ACS Med Chem Lett. 2015 Nov 2;6(12):1190-4. doi: 10.1021/acsmedchemlett.5b00322. eCollection 2015 Dec 10.

10.

Medical mirroring: granulomatosis with polyangiitis (formerly Wegener's) mimicking immunoglobulin-G4 related disease.

Kaushik P, Stone JH, Anderson JT, Dugar S, Mathew R, Nikolic B, Patel R.

Int J Rheum Dis. 2018 Apr;21(4):885-889. doi: 10.1111/1756-185X.12687. Epub 2015 Jul 31.

PMID:
26234733
11.

Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.

Dugar S, Hollinger FP, Kuila B, Arora R, Sen S, Mahajan D.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3142-6. doi: 10.1016/j.bmcl.2015.06.007. Epub 2015 Jun 10.

PMID:
26112437
12.

Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (-)-epicatechin in healthy volunteers.

Barnett CF, Moreno-Ulloa A, Shiva S, Ramirez-Sanchez I, Taub PR, Su Y, Ceballos G, Dugar S, Schreiner G, Villarreal F.

Food Funct. 2015 Mar;6(3):824-33. doi: 10.1039/c4fo00596a.

13.

Non-destructive monitoring of charge-discharge cycles on lithium ion batteries using ⁷Li stray-field imaging.

Tang JA, Dugar S, Zhong G, Dalal NS, Zheng JP, Yang Y, Fu R.

Sci Rep. 2013;3:2596. doi: 10.1038/srep02596.

14.

Solid-state STRAFI NMR probe for material imaging of quadrupolar nuclei.

Tang JA, Zhong G, Dugar S, Kitchen JA, Yang Y, Fu R.

J Magn Reson. 2012 Dec;225:93-101. doi: 10.1016/j.jmr.2012.10.009. Epub 2012 Oct 26.

PMID:
23151490
15.

Increasing 13C CP-MAS NMR resolution using single crystals: application to model octaethyl porphyrins.

Dugar S, Fu R, Dalal NS.

J Phys Chem B. 2012 Aug 2;116(30):9215-22. doi: 10.1021/jp302189r. Epub 2012 Jul 24.

PMID:
22679901
16.

Outsourcing drug discovery to India and China: from surviving to thriving.

Subramaniam S, Dugar S.

Drug Discov Today. 2012 Oct;17(19-20):1055-8. doi: 10.1016/j.drudis.2012.04.005. Epub 2012 Apr 19.

PMID:
22542471
17.

Circadian variation in ictus of aneurysmal subarachnoid hemorrhage.

Temes RE, Bleck T, Dugar S, Ouyang B, Mohammad Y, John S, Patel P, Lee V, Prabhakaran S, Quigg M.

Neurocrit Care. 2012 Apr;16(2):219-23. doi: 10.1007/s12028-011-9640-6.

PMID:
22045245
18.

Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides.

Tester R, Tan X, Luedtke GR, Nashashibi I, Schinzel K, Liang W, Jung J, Dugar S, Liclican A, Tabora J, Levy DE, Do S.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3. doi: 10.1016/j.bmcl.2010.02.090. Epub 2010 Mar 2.

PMID:
20346659
19.

Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.

Luedtke GR, Schinzel K, Tan X, Tester RW, Nashashibi I, Xu YJ, Dugar S, Levy DE, Jung J.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2556-9. doi: 10.1016/j.bmcl.2010.02.088. Epub 2010 Mar 10.

PMID:
20346653
20.

Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles.

Tan X, Tester RW, Luedtke GR, Chakravarty S, Mavunkel BJ, Perumattam JJ, Lu Q, Nashashibi I, Jung J, Hu J, Liclican A, Almirez R, Tabora J, Tran V, Laney M, Levy DE, Dugar S.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):828-31. doi: 10.1016/j.bmcl.2009.12.091. Epub 2010 Jan 4.

PMID:
20071169
21.

Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.

Mavunkel BJ, Perumattam JJ, Tan X, Luedtke GR, Lu Q, Lim D, Kizer D, Dugar S, Chakravarty S, Xu YJ, Jung J, Liclican A, Levy DE, Tabora J.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1059-62. doi: 10.1016/j.bmcl.2009.12.031. Epub 2009 Dec 11.

PMID:
20031411
22.

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.

Medicherla S, Wadsworth S, Cullen B, Silcock D, Ma JY, Mangadu R, Kerr I, Chakravarty S, Luedtke GL, Dugar S, Protter AA, Higgins LS.

Diabetes Metab Syndr Obes. 2009 Jun 23;2:91-100.

23.

Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain.

Svensson CI, Medicherla S, Malkmus S, Jiang Y, Ma JY, Kerr I, Brainin-Mattos J, Powell HC, Luo ZD, Chakravarty S, Dugar S, Higgins LS, Protter AA, Yaksh TL.

Pharmacol Biochem Behav. 2008 Oct;90(4):664-75. doi: 10.1016/j.pbb.2008.05.016.

PMID:
18584857
24.

Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation.

Lu Q, Chen Z, Perumattam J, Wang DX, Liang W, Xu YJ, Do S, Bonaga L, Higaki J, Dong H, Liclican A, Sideris S, Laney M, Dugar S, Mavunkel B, Levy DE.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2399-403. doi: 10.1016/j.bmcl.2008.02.057. Epub 2008 Mar 4.

PMID:
18337095
25.

Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 2: SAR of the amine tether.

Levy DE, Wang DX, Lu Q, Chen Z, Perumattam J, Xu YJ, Higaki J, Dong H, Liclican A, Laney M, Mavunkel B, Dugar S.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2395-8. doi: 10.1016/j.bmcl.2008.02.058. Epub 2008 Mar 4.

PMID:
18334295
26.

Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 1: SAR of the aryl region.

Levy DE, Wang DX, Lu Q, Chen Z, Perumattam J, Xu YJ, Liclican A, Higaki J, Dong H, Laney M, Mavunkel B, Dugar S.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2390-4. doi: 10.1016/j.bmcl.2008.02.059. Epub 2008 Mar 4.

PMID:
18334294
27.

Pyrimidine-based inhibitors of CaMKIIdelta.

Mavunkel B, Xu YJ, Goyal B, Lim D, Lu Q, Chen Z, Wang DX, Higaki J, Chakraborty I, Liclican A, Sideris S, Laney M, Delling U, Catalano R, Higgins LS, Wang H, Wang J, Feng Y, Dugar S, Levy DE.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2404-8. doi: 10.1016/j.bmcl.2008.02.056. Epub 2008 Mar 4.

PMID:
18334293
28.

Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.

Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS.

Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7.

PMID:
18176091
29.

p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.

Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS.

J Pharmacol Exp Ther. 2008 Mar;324(3):921-9. Epub 2007 Dec 4.

30.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH.

Neuro Oncol. 2007 Jul;9(3):259-70. Epub 2007 May 23. Erratum in: Neuro Oncol. 2007 Oct;9(4):465.

31.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

Kirkwood KL, Li F, Rogers JE, Otremba J, Coatney DD, Kreider JM, D'Silva NJ, Chakravarty S, Dugar S, Higgins LS, Protter AA, Medicherla S.

J Pharmacol Exp Ther. 2007 Jan;320(1):56-63. Epub 2006 Oct 13.

32.

Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.

Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30.

33.

Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.

Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G, Protter AA.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1972-7. Epub 2006 Jun 2.

34.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

35.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
36.

Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.

Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF.

J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. Epub 2006 Apr 7.

37.

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.

Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA.

J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. Epub 2006 Apr 5.

38.

Committee on Additives, Beverages, and Food Process-Related Analytes.

Dugar SM, Hill NR, Bhandari SD, Byington JI, Canas BJ, Eckermann C, Hageman LR, Kupina S, Reid AP, Reimann LM, Scalese J, Thomas LC, Cereijo MI.

J AOAC Int. 2005 Jan-Feb;88(1):363-6. No abstract available.

PMID:
15759762
39.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Lim MY, Wang H, Kapoun AM, O'connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, Protter AA, Higgins LS.

J Mol Cell Cardiol. 2004 Dec;37(6):1111-4.

PMID:
15572041
40.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.

Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98. Epub 2004 Nov 24.

PMID:
15563636
41.

p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.

Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, Protter AA.

J Cardiovasc Pharmacol. 2004 Oct;44(4):486-92.

PMID:
15454858
42.

Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia.

Sweitzer SM, Peters MC, Ma JY, Kerr I, Mangadu R, Chakravarty S, Dugar S, Medicherla S, Protter AA, Yeomans DC.

Pain. 2004 Oct;111(3):278-85.

PMID:
15363871
43.

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M.

Cancer Res. 2004 Aug 1;64(15):5200-11.

44.

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

Ge R, Rajeev V, Subramanian G, Reiss KA, Liu D, Higgins L, Joly A, Dugar S, Chakravarty J, Henson M, McEnroe G, Schreiner G, Reiss M.

Biochem Pharmacol. 2004 Jul 1;68(1):41-50.

PMID:
15183116
45.

Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model.

Sweitzer SM, Medicherla S, Almirez R, Dugar S, Chakravarty S, Shumilla JA, Yeomans DC, Protter AA.

Pain. 2004 Jun;109(3):409-19.

PMID:
15157702
46.

Isopropyl amide derivatives of potent and selective muscarinic M2 receptor antagonists.

Palani A, Dugar S, Clader JW, Greenlee WJ, Ruperto V, Duffy RA, Lachowicz JE.

Bioorg Med Chem Lett. 2004 Apr 5;14(7):1791-4.

PMID:
15026073
47.

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.

Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, Xu YJ, Laney M, Liu DY, Schreiner GF, Lewicki JA, Dugar S.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3087-90.

PMID:
12941340
48.

Analysis of ethyl carbamate in wines using solid-phase extraction and multidimensional gas chromatography/mass spectrometry.

Jagerdeo E, Dugar S, Foster GD, Schenck H.

J Agric Food Chem. 2002 Oct 9;50(21):5797-802.

PMID:
12358441
49.

Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.

Ahmad S, Doweyko LM, Dugar S, Grazier N, Ngu K, Wu SC, Yost KJ, Chen BC, Gougoutas JZ, DiMarco JD, Lan SJ, Gavin BJ, Chen AY, Dorso CR, Serafino R, Kirby M, Atwal KS.

J Med Chem. 2001 Sep 27;44(20):3302-10.

PMID:
11563929
50.

Benzylidene ketal derivatives as M2 muscarinic receptor antagonists.

Boyle CD, Chackalamannil S, Chen LY, Dugar S, Pushpavanam P, Billard W, Binch H 3rd, Crosby G, Cohen-Williams M, Coffin VL, Duffy RA, Ruperto V, Lachowicz JE.

Bioorg Med Chem Lett. 2000 Dec 18;10(24):2727-30.

PMID:
11133078

Supplemental Content

Support Center